Entity
  • Tubulis GmbH

    Created in 2012
  • BETA

    Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups
  • Social networks

    159 4,564
  • Activities

  • Technologies

  • Entity types

  • Location

    81377 Munich, Germany

    Munich

    Germany

  • Employees

    Scale: 51-200

    Estimated: 46

  • Engaged corporates

    3
    2 1
  • Added in Motherbase

    3 years, 6 months ago
Description
  • Value proposition

    Reimagining ADCs.

    Tubulis® generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

    Antibody Drug Conjugates, Targeted Therapy, Biotechnology, and Drug Development

Corporate interactions BETA
Corporate TypeTweets Articles
Seventure Partners
Seventure Partners
Startup accelerator & VC, Venture Capital and Private Equity Principals
Seventure Partners
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

18 Mar 2024


Bristol Myers Squibb
Bristol Myers Squibb
Pharmaceutical, Pharmaceutical Manufacturing
Bristol Myers Squibb
Pharmaceutical, Pharmaceutical Manufacturing
Other

20 Apr 2023

20 Apr 2023



HTGF | High-Tech Gründerfonds
HTGF | High-Tech Gründerfonds
Venture Capital and Private Equity Principals
HTGF | High-Tech Gründerfonds
Venture Capital and Private Equity Principals
Capitalistic
Partnership
Not event

21 Jul 2020


Similar entities
Loading...
Loading...
Social network dynamics